Nan Sethakorn, MD
Medical Oncology, Hematology & Oncology, Internal Medicine
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
888-584-7888
Accepting New Patients
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Primary Contact
888-584-7888Services & Specialties
Areas of Specialization
- Hematology & Oncology
- Internal Medicine
- Medical Oncology
Clinical Interests
Conditions Treated
- cancer chemotherapy
- targeted molecular therapy
- cancer immunotherapy
- lung cancer
Locations & Contact
Primary Location
Loyola University Medical Center
2160 S First Ave
Maywood, IL 60153
About
I am a physician-scientists focusing on the treatment of patients with lung cancer, and in the laboratory I study how the tumor microenvironment (TME) in bone metastases affect treatment responses of lung cancer using tumor organoids and non-cancerous cells donated from patients. The goal of our research is to find new ways to overcome treatment resistance and new ways to treat bone metastases, both of which are major concerns in the treatment of lunch cancer.
Academic Title
Assistant Professor
Ages Seen
Education & Certifications
Education
Education:
University of Chicago,Pritzker School of Medicine
(2015)
Education:
University of Chicago Division of Biological Sciences Pritzker School of Medicine
(2015)
Residency:
University of Wisconsin Hospitals and Clinics (Madison)
(2017)
Fellowship:
University of Wisconsin Hospitals and Clinics (Madison)
(2021)
Fellowship:
University of Wisconsin Hospitals and Clinics (Madison)
(2021)
Board Certifications
Medical Oncology, Medical Oncology, American Board of Internal Medicine Subspecialty (2021)
Internal Medicine, Internal Medicine, American Board of (2018)
Internal Medicine, American Board of (2018)
Provider Groups
Loyola Medicine Physician
Loyola Physician Partners
Publications
- The future promise of antibody-drug conjugates in extensive-stage small cell lung cancer. Sethakorn, N.; Chiang, A. C.; Cancer
- Clinical overview of trophoblast surface antigen 2 antibody-drug conjugates in non-small cell lung cancer. Patel, S. P.; Gadgeel, S.; Mino-Kenudson, M.; Naidoo, J.; Sethakorn, N.; Cancer treatment reviews
- Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances. McLaughlin, Q.; Sojka, D. K.; Kennedy, K.; Piersma, S. J.; Sethakorn, N.; Journal of experimental & clinical cancer research : CR
- Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response. Sánchez-de-Diego, C.; Yada, R. C.; Sethakorn, N.; Geiger, P. G.; Ding, A. B.; Heninger, E.; Ahmed, F.; Virumbrales-Muñoz, M.; Lupsa, N.; Bartels, E.; Stewart, K.; Ponik, S. M.; Sharifi, M. N.; Lang, J. M.; Beebe, D. J.; Kerr, S. C.; Communications biology
- Combining Dual Checkpoint Immunotherapy with Ablative Radiation to All Sites of Oligometastatic Non-Small Cell Lung Cancer: Toxicity and Efficacy Results of a Phase 1b Trial. Bassetti, M. F.; Morris, B. A.; Sethakorn, N.; Lang, J. M.; Schehr, J. L.; Zhao, S. G.; Morris, Z. S.; Buehler, D.; Eickhoff, J. C.; Harari, P. M.; Traynor, A. M.; Campbell, T. C.; Baschnagel, A. M.; Leal, T. A.; International journal of radiation oncology, biology, physics